期刊文献+

过表达SSTR2通过多种信号途径抑制SSTR2表达阳性的肿瘤生长 被引量:5

Overexpression of SSTR2 inhibits growth of SSTR2-positive tumors via multiple signaling pathways
下载PDF
导出
摘要 目的:研究转基因SSTR2对有不同内源性SSTRs表达谱的癌细胞增殖抑制及其潜在信号途径。方法:在裸鼠身上接种过表达SSTR2或LacZ的capan-2cell和A549细胞,观察肿瘤生长情况。在裸鼠身上构建capan-2移植瘤模型,通过皮下注射携带SSTR2基因的腺病毒,观察肿瘤生长情况。免疫印迹法分析可能涉及的信号途径。结果:过表达SSTR2能够抑制具有不同内源性SSTRs表达谱肿瘤的生长,包括capan-2具有内源性SSTR2表达。SSTR2过表达明显影响了凋亡途径、MAPK途径以及血管生成中的一些组件。结论:SSTR2有希望成为使用转基因治疗多数癌症的候选基因。 AIM: To study the anti - proliferation effect of overexpressed SSTR2 in experimental cancer with different profiles of endogenous SSTRs expressions and the possible signaling pathways involved. METHODS: In the first experiment, the growth of the tumor xenografts of the inoculated capan - 2 cells and A549 cells overexpressing SSTR2 or LacZ was investigated in nude mice. In the second experiment, the adenoviral vector expressing SSTR2 were introduced into experimental capan -2 xenografts by intratumoral injection. The growth inhibition of these experiment tumors was observed and the potential influences on different signaling pathways were analyzed by immunoassays. RESULTS: Overexpression of SSTR2 inhibited the growth of tumors with different profiles of endogenous SSTRs, including experimental capan - 2 xenografts that had endogenous SSTR2 expression. Overexpression significantly affected a number of components in apoptotic pathway, MAPK pathway and angiogenesis. CONCLUSION: SSTR2 is a promising candidate for gene therapy in a wide spectrum of cancers.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2009年第7期1254-1261,共8页 Chinese Journal of Pathophysiology
基金 国家自然科学基金资助项目(No.90608024) 广东省自然科学基金资助项目(No.81510632 No.010000013) 教育部科学技术研究重点资助项目(No.207144)
关键词 受体 生长抑素 腺病毒 异种移植 Receptors, somatostatin Adenovirus Xenograft
  • 相关文献

参考文献2

二级参考文献23

  • 1华赟鹏,李绍强,赖佳明,梁惠珍,梁力建,黄洁夫.奥曲肽调节自身受体2在肝癌上的表达及其影响[J].中国病理生理杂志,2004,20(12):2325-2329. 被引量:6
  • 2Reisine T. Somatostatin. Cell Mol Neurobiol, 1995, 15:597-614.
  • 3Delesque N, Buscail L, Esteve JP, et al. sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res, 1997, 57:956-962.
  • 4Buscail L, Saint-Laurent N, Chastre E, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res, 1996, 56:1823-1827.
  • 5Van Eijck CH, Lamberts SW, Lemaire LC, et al. The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann Surg, 1996, 224:119-124.
  • 6Reubi JC, Horisberger U, Essed CE, et al. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology, 1988, 95:760-763.
  • 7Fekete M, Zalatnai A, Comaru-Schally AM, et al. Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas, 1989, 4:521-528.
  • 8Srkalovic G, Cai RZ, Schally AV. Evaluation of receptors for somatostatin in various tumors using different analogs. J Clin Endocrinol Metab, 1990, 70:661-669.
  • 9Sulkowski U, Buchler M, Pederzoli P, et al. A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma. Eur J Cancer, 1999, 35:1805-1808.
  • 10Burch PA, Block M, Schroeder G, et al. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study. Clin Cancer Res, 2000

共引文献25

同被引文献22

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部